ENPP1 and tuberculosis: Hence, for the ENPP1 inhibitors identified in our study to be valuable for TB therapy, our focus of future preclinical in vitro and in vivo studies will be to establish optimal drug concentrations, duration of treatment, and efficacy in combination with standard anti-mycobacterial therapies in preclinical in vitro and in vivo studies in order to support transient increases of the type I IFN response and minimize long-term hyperinflammation.